Program

Lead Indication

Preclinical

Phase 1

Phase 2

Phase 3

Affiliate Company1

PCN-101 / Rketamine

Treatment-Resistant Depression

Phase 2

Phase 2

Perception Neuroscience

RL-007 / Compound2

Cognitive Impairment Associated With Schizophrenia

Phase 2

Phase 2

Recognify Life Sciences

GRX-917 / Deuterated etifoxine

Generalized Anxiety Disorder

Phase 1

Phase 1

GABA Therapeutics

DMX-1002 / Ibogaine

Opioid Use Disorder

Phase 1

Phase 1

DemeRx IB

KUR-101 / Deuterated mitragynine

Opioid Use Disorder

Phase 1

Phase 1

Kures

VLS-01 / DMT

Treatment-Resistant Depression

Phase 1

Phase 1

Viridia Life Sciences

EMP-01 / MDMA derivative

Post-Traumatic Stress Disorder

Phase 1

Phase 1

EmpathBio

LIMITED TO EQUITY INTEREST

COMP360 / Psilocybin3

Treatment-Resistant Depression

Phase 3

COMPASS Pathways

Phase 3

COMP360 / Psilocybin3

Post-Traumatic Stress Disorder

Phase 2

COMPASS Pathways

Phase 2

COMP360 / Psilocybin3

Anorexia Nervosa

Phase 2

COMPASS Pathways

Phase 2

Note: DMT = N,N-dimethyltryptamine; MDMA = 3,4-Methyl​enedioxy​methamphetamine

(1) Perception, Recognify, and DemeRx IB are all variable interest entities; GABA is a non-consolidated VIE with operational involvement through MSA model; EmpathBio and Viridia are wholly-owned subsidiaries; COMPASS Pathways is a non-controlling equity interests

(2) RL-007 compound is (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salts

(3) Developing COMP360, a formulation of psilocybin, administered with psychological support from specially trained therapists

Our Technologies

Introspect

Introspect believes that high-quality digital combination therapies will increase the safety and effectiveness of many mental health drugs. Digital therapeutics (DTx) will provide personalized and scalable treatment to those who might not otherwise be able to access high-quality psychological care.

introspect.digital

accordion image LEARN MORE
EntheogeniX

Psilocybin, ibogaine, and many other psychedelic substances have yielded remarkable early signals of their efficacy in treating everything from depression to various forms of addiction. And while Dr. Srinivas Rao, Chief Executive Officer of EntheogeniX Biosciences, shares the cautious optimism of many researchers, he’s careful to point out that these and other substances come with two significant obstacles…

entheogenixbio.com

accordion image LEARN MORE
InnarisBio

InnarisBio specialized in drug formulation bringing its sol-gel based, intranasal excipient technology to atai. The novel technology may enable new drug formulations with unique and optimized modes of delivery across various active ingredients in the atai pipeline, as well as potential assets in the future. 

innaris.bio

accordion image LEARN MORE
PsyProtix

PsyProtix is taking a precision psychiatry approach to develop metabolomics-based biomarkers to stratify patients with treatment-resistant depression (TRD) and other mental health indicationsBy identifying patient subsets with unique metabolic profiles, PsyProtix will test mechanism-based treatments with the goal of improving overall outcomes.

accordion image LEARN MORE
JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on atai and innovations in the space.

Email
submit